693 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure http://www.zacks.com/stock/news/521160/astrazenecas-farxiga-gets-fast-track-tag-for-heart-failure?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-521160 Sep 16, 2019 - The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-ZC-FT-analyst_blog|industry_focus-520833 Sep 16, 2019 - The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-ZC-FT-analyst_blog|stock_roundup-516828 Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Top Analyst Reports for Caterpillar, General Motors & Citigroup http://www.zacks.com/research-daily/511170/top-analyst-reports-for-caterpillar-general-motors-citigroup?cid=CS-ZC-FT-research_daily-511170 Sep 10, 2019 - Top Analyst Reports for Caterpillar, General Motors & Citigroup
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice http://www.zacks.com/stock/news/510993/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-510993 Sep 10, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow https://seekingalpha.com/article/4290610-eli-lilly-company-lly-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=feed_sector_healthcare Sep 09, 2019 - The following slide deck was published by Eli Lilly and Company in conjunction with this event.
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509890 Sep 09, 2019 - Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Novartis Announces Positive Long-Term Data on Migraine Drug http://www.zacks.com/stock/news/509529/novartis-announces-positive-long-term-data-on-migraine-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509529 Sep 09, 2019 - Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
4 Biotech Stocks With Big Catalysts in September https://www.fool.com/investing/2019/09/05/biotech-stocks-with-big-catalysts-in-september.aspx?source=iedfolrf0000001 Sep 05, 2019 - Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503575 Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.

Pages: 1...56789101112131415...70

<<<Page 10>